Your Treatment Plan Requires Diagnostic Certainty1

Actor portrayals

Differentiate true tumor progression from treatment-related change

Lesion-based, patient-level performance of Pixclara® (18F-FET) PET as a single-imaging strategy for detection of recurrent or progressive glioma across 2 clinical studiesa

Positive percent agreement (PPA)b and negative percent agreement (NPA)c
across 3 independent readers

Study 1 (n=127)

PPAd

Reader 1

73%

(61, 82)

Reader 2

83%

(73, 90)

Reader 3

70%

(58, 79)

NPAd

Reader 1

59%

(47, 71)

Reader 2

48%

(36, 60)

Reader 3

64%

(51, 75)

Study 2 (n=254)

PPAd

Reader 1

66%

(58, 74)

Reader 2

72%

(64, 79)

Reader 3

67%

(58, 75)

NPAd

Reader 1

61%

(52, 69)

Reader 2

53%

(44, 61)

Reader 3

57%

(48, 55)

Study 1: Clinical study evaluating Pixclara® PET to differentiate recurrent or progressive glioma from treatment-related change in patients with intracranial neoplasms following primary treatment with radiation therapy, surgery, or both. The image analysis cohort included 127 patients (116 adults, 11 pediatric patients [7 adolescents aged 12-16 years, 4 children aged 5-11 years]) with suspected recurrent or progressive glioma of any grade. Adult patients received 217 ± 23 MBq (5.9 ± 0.63 mCi) and pediatric patients received 155 ± 54 MBq (4.2 ± 1.4 mCi) of Pixclara® followed by PET/MRI of the brain.

Study 2: Clinical study evaluating Pixclara® PET to differentiate recurrent or progressive glioma from treatment-related change in patients with known or suspected glioma of any grade treated with surgery, radiation, or chemotherapy, and suspected disease recurrence or progression on MRI. The efficacy analysis included 254 patients (253 adults and 1 adolescent aged 16 years). Adult patients received 201 ± 22 MBq (5.4 ± 0.58 mCi) of Pixclara® and the pediatric patient received 181 MBq (4.9 mCi) followed by PET/CT or PET/MRI of the brain.

A multidisciplinary panel without access to blinded reader assessments or Pixclara® PET images determined composite reference standard results, assessing lesions as tumor or treatment-related change based on histopathology, clinical, surgical, and conventional imaging reports, and MRI results obtained before, with, and after Pixclara®.

aFor a given reader, the patient-level result is determined from the lesion-level result(s) using a composite reference standard. For Study 2, results are consistent with a tipping point analysis (p=0; missing PET imputed as negative), and the numbers of reference-positive and reference-negative patients are consistent across readers.

bPPA represents the percentage of patients with a positive Pixclara® PET result among those who were reference standard positive.

cNPA represents the percentage of patients with a negative Pixclara® PET result among those who were reference standard negative.

d95% confidence interval (CI).

Pixclara® demonstrated diagnostic performance in differentiating benign treatment-related change from recurrent or progressive glioma across 2 clinical studies, including in a real-world setting1

See how Pixclara® can help guide treatment decisions.

Explore Data

CT, computed tomography; MBq, megabecquerel; mCi, millicurie; MRI, magnetic resonance imaging; PET, positron emission tomography.